Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
FLX475 is a CCR4 antagonist, which potentially results in increased effector T-cell and decreased regulatory T-cells within the tumor microenvironment, leading to antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|FLX475 + Ipilimumab||FLX475 Ipilimumab||0||1|
|FLX475 + Pembrolizumab||FLX475 Pembrolizumab||0||1|